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Abstract
Endoscopic stenting has become a widely method for 
the management of various malignant and benign 
pancreatico-biliary disorders. Biliary and pancreatic 
stents are devices made of plastic or metal used 
primarily to establish patency of an obstructed bile 
or pancreatic duct and may also be used to treat 
biliary or pancreatic leaks, pancreatic fluid collections 
and to prevent post-endoscopic retrograde cholangio-
pancreatography pancreatitis. In this review, relevant 
literature search and expert opinions have been used 
to evaluate the outcome of stenting in biliary and 
pancreatic benign and malignant diseases.
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Core tip: Endoscopic stenting plays an indispensable role 
in the treatment of benign and malignant pancreatico-
biliary disorders. This article will cover the indications 
and outcome of stenting in bilio-pancreatic disease.
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INTRODUCTION
Endoscopic stenting has become a widely used method 
for the management of various malignant and benign 
pancreatico-biliary disorders.
Biliary and pancreatic plastic or metal stents are 
used primarily to establish patency of an obstructed bile 
duct or main pancreatic duct (MPD) but may also be 
used to treat biliary or pancreatic leaks, cholecystitis, 
large non-removable common bile duct (CBD) stones, 
pancreatic fluid collections (PFCs) and to prevent post 
endoscopic retrograde cholangiopancreatography 
(ERCP) pancreatitis (PEP).
This paper will cover the indications an outcome of 
the different types of stents currently used, techniques 
of placement, established and upcoming indications, 
and complications associated with stent use.
BENIGN BILIARY DISEASES
Benign biliary strictures
Benign biliary strictures (BBSs) can be caused by post-
operative injury (particularly after cholecystectomy), 
anastomotic injury following orthotopic liver transplanta-
tion (OLT), chronic pancreatitis (CP), primary sclerosing 
cholangitis (PSC), post-endoscopic sphincterotomy (ES) 
and other less frequent conditions, such as radiation 
therapy, IgG4 involvement of the bile ducts and portal 
biliopathy[1]. 
The choice of the type and the number of stents is 
dependent mainly on the etiology of BBSs.
In patients with PSC a single plastic stent (PS) for 
a dominant bile duct stricture can be sufficient, while 
for most of these diseases the standard endotherapy is 
dilation with placement of two or more PSs[2,3].
Bergman et al[4] treated patients with post-
cholecystectomy BBSs with two 10 Fr PSs during one 
year with exchange every three months and in the 
cohort patients that completed the 12-mo stenting 
period, during nine years of follow-up achieved a 
clinical success rate of 80%.
In similar patients, Costamagna et al[5] placed the 
maximum number of PSs (until four 10 Fr could be 
placed in the first ERCP) during a year with exchanges 
every three months and during a 4 years of follow-up 
achieved a clinical success rate of 97.5%.
These good results were confirmed in the same 
cohort after a long follow-up (mean 13.7 years, range 
11.7 to 19.8) with an 11% stricture recurrence rate, 
always successfully retreated endoscopically[6].
This approach of progressive dilation with an 
increasing number of PSs have been undertaken in 
patients with post-OLT BBSs either anastomotic or 
non-anastomotic[7-9], in CP strictures[10], or in post-ES 
strictures[11].
However an important limitation of the multi-
stenting strategy is the need of 3 to 4 ERCPs sessions 
over the one-year period, with implications of patient 
satisfaction and quality of life, along with important 
implications for health care costs.
Moreover, while are reported favourable results 
of endoscopic plastic stenting for post-operative 
BBSs (post-cholecystectomy and post-OLT) with a 
recurrence rate of 20% to 30%, approximately 80% 
of patients with CP treated with plastic stenting may 
eventually develop relapse of strictures[1].
For these reasons, there continues to be high 
interest in pursuing alternative endoscopic approaches 
that may achieve comparable or better results while 
requiring fewer interventions.
In this setting the use of self-expandable metal 
stent (SEMS) is an attractive alternative to single or 
multiple PSs for treatment of BBSs for several technical 
and economic reasons.
It is technically difficult to place several PSs during 
the initial endoscopic procedure due to the diameter 
of the stricture and the size of the bile duct below 
the stricture. The small diameter delivery system of 
metal stent allows placement without stricture dilation 
enabling an easier endoscopic procedure, whilst 
a single metal stent expands to a large diameter, 
equivalent to three 10 Fr PSs and can remain in place 
for a prolonged period of time before removal.
PSs have a limited patency that requires frequent 
stent exchanges to prevent or manage stent occlusion. 
Metal stents may allow dilation of a benign stricture 
without the need for progressive stent upsizing, 
thereby reducing the number of requisite ERCPs, so 
the higher cost of metal stent may be offset by the 
decrease in ERCPs.
A tapered deployment catheter is likely to obviate 
the need for pre-treatment with balloon or passage 
dilation, thereby reducing the number of devices 
needed at the time of initial ERCP.
The superior patency of metal stent may lower the 
cumulative number of ERCPs and time required to fully 
dilate a BBS. 
The initial increased cost of a metal stent compared 
with one or more PSs should be offset by the need to 
perform fewer procedures.
Uncovered self-expandable metal stents (USEMSs) 
are not recommended for treatment of BBSs because 
tissue ingrowth through the mesh of the stent make 
stent removal impossible, while for this purpose metal 
stents must be partially-covered (PC), or even better, 
fully-covered (FC).
The use of PC-SEMSs showed good result, with a 
technical success of 100% and clinical success rates of 
75% to 90% in both post-operative and inflammatory 
BBSs[12,13].
However, tissue ingrowth through the uncovered 
areas of stent mesh leads to both premature stent 
obstruction and embedding of the stent into the biliary 
wall, making future retrieval of the PC-SEMS difficult 
and was also noted in some cases that the tissue 
hyperplasia at the proximal uncovered portion of the 
stent resulting in a new stricture[14].
Because of limitations related PC-SEMSs, parti-
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cularly tissue ingrowth at the uncovered portions, FC-
SEMSs were introduced for the treatment of BBSs. The 
absence of epithelial hyperplasia and embedding of an 
FCSEMS also allows the possibility of leaving the stent 
in situ for more than 6 mo, if required. 
However, in early reports, stent migration was 
common because of the nature of the FCSEMS used.
Stent migration has been reported to range from 
4% to 40%[15-17].
Several designs for anti-migration properties of FC-
SEMSs have been developed such as stents with flared 
ends, anchoring fins and anchoring flaps.
Among studies using stents with anchoring fins to 
prevent migration, Mahajan et al[18] achieved a very 
high (83%) improvement in biliary stricture with a 
migration rate of 4.5%, but stent removal was not 
easy and at cholangioscopic examination, performed 
in half of the patients after stent removal, found biliary 
mucosal ulcer formation and haemorrhage induced by 
the anchoring fins.
The use of FC-SEMSs with flared ends was reported 
in single and multicenter studies with good resolution 
rate of BBSs, but with a migration rate ranging 
between 10% and 31%[19-21].
To overcome the problem of the migration, the use 
of stent with anchoring flaps design showed excellent 
results.
Park et al[22] compared two types of FC-SEMS in 
43 patients with BBSs; one stent had four anchoring 
flaps at the proximal end and flared distal end, and 
the other had flared end at both proximal and distal 
parts without anchoring flaps. After a median of 6 mo, 
no migration occurred in patients in the anchoring 
flaps group, while the 33% of patients in the flared 
end group had migration (P = 0.004). In both groups 
the FC-SEMSs were removed without difficulty and an 
immediate improvement of biliary stricture was 91% 
in the anchoring flaps group and 88% in the flared end 
group.
These results were also confirmed in a recently 
prospective multicenter study, in which 24 patients 
with BBSs were treated with the placement of a 
FC-SEMS with double lasso and anchoring flaps as 
first-line therapy. Technical and clinical success were 
100% and only one late stent migration occurred 
(3.3%)[23].
Also with the use of metal stents in most of the 
published studies stricture resolution rate was noted to 
be lowest in patients with CP.
However a recent systematic review of the studies 
published from 2000 to 2012 compared the feasibility, 
success rate, and complications rate of covered SEMS 
(376 cases) with multiple PSs (570 cases) in patients 
with BBSs and showed a significantly higher clinical 
success rate (P = 0.006) for covered SEMS (77%) 
compared to PS (33%) in strictures related to CP at 12 
mo follow-up and the incidence of late adverse events 
was lower in patients treated with covered SEMSs 
compared to PSs (P = 0.02); there were no differences 
in the success rates of other etiologies, but in all types 
of BBSs the median number of ERCPs was significantly 
lower (P = 0.002) with covered SEMSs compared to 
PSs (1.5 vs 3.9)[24].
Biliary stones
When endoscopic removal of CBD stones fail, insertion 
of plastic biliary stent to bypass the stone is a useful 
alternative[25].
Both 7 and 10 Fr straight and double pigtail stents 
have been used to drain the CBD in patients with 
irretrievable CBD stones. Placement of a stent is 
mandatory if biliary clearance cannot be achieved 
during ERCP, and can be placed temporarily in patients 
who require more than one session for clearance.
Biliary stenting not only provides a temporary 
conduit for bile outflow, but stent placement may allow 
stone extraction to be more successful on the next 
endoscopic attempt, because the mechanical irritation 
of the stent due to continuous friction and enhanced 
by body and intestinal movements, reduce the size of 
the stone and increase stone fragmentation.
The technical success rate of plastic biliary stenting 
for CBD stones has been reported to be nearly 100% 
and the rate of successful stone removal during follow-
up has been reported to range from 44% to 92%[26].
Recurrent cholangitis is the most frequent 
complication of stent occlusion reported between 
3.5% and 40%. To prevent this complication a recent 
RCT compared a group of patients in whom PSs were 
changed every 3 mo or sooner if symptoms appeared 
to a group of patients in whom the PSs were changed 
on demand at the onset of symptoms[27]. The results, 
suggests stent exchange every 3 mo is the preferred 
approach[27]. Other complications are stent migration 
and clogging.
Although metal stents are usually not used in CBD 
stones, some studies have shown that metal stents have 
an advantage over PSs in improving subsequent duct 
clearance and to prevent long-term complications[28,29].
The large diameter of metal stents may facilitate 
subsequent clearance of bile duct stones, potentially 
through exerting radial forces to affect stone 
fragmentation and papillary dilation. Long-term patency 
may also make metal stent placement an option for 
patients in whom long-term stenting is desired for any 
reasons.
Biliary leaks
Biliary leaks (BLs) are most often a consequence of 
surgery, such as open or laparoscopic cholecystectomy, 
OLT and hepatic resection, trauma, or invasive procedures, 
such as liver biopsy and percutaneous transhepatic 
cholangiography[30].
A variety of endoscopic techniques have been used 
to manage BLs. These include ES alone, placement of 
PS with or without ES, and nasobiliary drainage with 
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adverse event rate ranging between 0% and 20% that 
include post-ERCP pancreatitis, bleeding, perforation 
of the cystic duct or gallbladder, stent occlusion, stent 
migration and sepsis[46-49].
In recent years, endoscopic ultrasonography (EUS) 
guided drainage has been reported as an alternative to 
the percutaneous transhepatic gallbladder drainage.
The EUS approach is comparable with radiological 
approach in terms of the technical feasibility, efficacy 
and safety, as proved in a recently randomized 
comparative study[50].
Endoscopic transpapillary gallbladder drainage 
is subject to low technical success rates due to non 
visualization of the cystic duct on cholangiography 
and failure of guidewire passage through the cystic 
duct into the gallbladder. In these circumstances, 
EUS-guided drainage is gaining favour as an effective 
alternative to the transpapillary technique of drainage.
In the first published studies of EUS-guided 
drainage, PSs were used. However, the placement of 
these stents often requires large tract dilatation, thus 
increasing the risk of bile leakage, distal migration and 
clogging, because their small caliber, which can limit 
bile flow, especially when the content of the gallbladder 
is thick.
A good alternative to the use of PSs for EUS-
guided drainage is the use of metal stents because 
of their larger diameters. Occlusion is less likely and 
can seal the gap between the stent and the fistula 
tract by its covering and expansion, thereby reducing 
the risk of bile leakage. However the risk of migration 
with subsequent leakage remains. Migration may be 
mitigated by placement of a double pigtail PS through 
the SEMS.
Recently specific FC-SEMSs have been designed to 
avoid these drawbacks by either enlarging and bending 
the flares at the ends of the stent 90°, or by means of 
a “saddle” shape with distal anchor flanges to ensure 
both lumen apposition and drainage[51,52].
The preliminary data on the use of lumen apposing 
metal stent (LAMS) for EUS-guided drainage showed 
mean technical and clinical success rates of 95% and 
95%, respectively and a mean overall adverse event 
rate of 5%[53,54].
These stents also have been shown to provide 
an additional advantage of allowing access to the 
gallbladder lumen using slim (< 10 mm) endoscope to 
perform biopsy, stone removal or debridement[55,56].
Bleeding
Post-ES and biliary bleeding were historically treated 
with endoscopic hemostatic techniques such as 
epinephrine injection, thermal therapy, balloon 
tamponade, clips, and placement of large bore PSs (10 
Fr or larger) to tamponade the bleeding site and to 
maintain biliary drainage (BD)[57].
Recently the use of covered metal stents have been 
reported for treatment of bleeding. These stents work 
or without ES. The goal of endoscopic treatment is to 
reduce the pressure gradient between the biliary tree 
and the duodenum, allowing preferential flow of bile 
into the duodenum and preventing outflow through the 
leak[31].
In a study of 207 patients with BL, Sandha et al[32] 
proposed an algorithm, recommending ES alone for 
minimal leaks (< 200 mL/24 h), insertion of a PS for 4 
to 6 wk for more severe leaks, presence of strictures, 
contraindication to ES or poor post-ES drainage. Using 
this strategy provides satisfactory results in more than 
90% of patients[32]. However in published studies the 
most frequently used approach is the placement of a 7 
Fr or 10 Fr stent with or without ES for 4 to 6 wk, with 
clinical success ranging between 90% and 100%[33-37].
The placement of PS has some disadvantages. 
When PSs are used at least one repeated procedure 
is necessary if occlusion or migration occurs. Further-
more, in patients with major BLs, such as those 
resulting from damage of the CBD or common hepatic 
duct (often associated with larger defects) multiple PSs 
can be inserted into the bile duct in order to fill the bile 
duct lumen and cross the site of the leak.
When endoscopic treatment fails, surgery remains 
an option but is not preferable for high-risk patients 
with severe comorbidities[38].
Recently, PC and FC-SEMS have been used to 
treat complex BLs, which are not responsive to plastic 
stenting and also as first-step endoscopic therapy, 
with a clinical success rate ranging between 70% and 
100%[39-42]. The use of metal stents not only reduces 
the pressure of the sphincter of Oddi but may also 
close the fistula area.
However metal stents cannot be routinely re-
commended for management of patients with post-
OLT BLs, because a high risk of post removal biliary 
strictures, especially if FC-SEMSs with fins are used[43].
Cholecystitis
Transpapillary gallbladder stenting can be considered 
in patients with acute calculous or acalculous 
cholecystitis when standard treatment options fail or 
are contraindicated. It is useful for patients who are 
critically ill and for those with severe comorbidity that 
precludes a surgical cholecystectomy and/or have 
contraindications for placement of a percutaneous 
cholecystostomy tube. Such patients include those with 
the presence of large amounts of ascites, coagulopathy, 
or an intervening loop of bowel between the diaphragm 
and the liver that precludes percutaneous access. 
Endoscopic stenting is contraindicated in patients with 
perforated gallbladder, who are too unstable to undergo 
endoscopy or sedation, or who are pregnant, because 
of the risks of radiation exposure from a prolonged 
procedure[44,45].
The technical success rate of transpapillary 
gallbladder stenting varies from 75% to 100%, with a 
clinical response rate between 70% and 100% and an 
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by tamponading the bleeding site while also providing 
drainage of the bile duct, especially when occluded by 
blood clots.
Both PC and FC-SEMS were used in a total of 52 
cases reported in the literature and based on these 
series two weeks of FC-SEMS placement is adequate in 
this setting[58,59].
Perforations
Traditionally, ERCP-related perforations have been 
managed surgically. However, only duodenal free 
wall perforations are treated with a prompt surgical 
intervention, while distal bile duct injuries that result 
from penetration of the guidewire through the bile 
duct during cannulation, or perivaterian perforations, 
occurring after ES, can be treated with a conservative 
approach with intravenous antibiotics, hydration, pain 
control and placement of PSs, to prevent bile leakage 
and formation of collections in the peritoneal or 
retroperitoneal space[60].
Recently the use of FC-SEMS have been reported 
to seal perforations (especially if the hole is large) and 
to prevent bile leakage into the perforation site.
A total of 28 cases are reported in literature and 
based on these series 4-6 wk of FC-SEMS placement is 
adequate in this setting[61].
MALIGNANT BILIARY DISEASES
Endoscopic stenting is the therapeutic modality of 
choice to decompress the biliary system in pancrea-
ticobiliary malignancies.
Distal malignant biliary obstruction (DMBO) is 
mainly caused by periampullary tumors, such as 
carcinoma of the papilla of Vater, pancreatic cancer 
and distal cholangiocarcinoma, and less commonly by 
gallbladder carcinoma and metastatic diseases.
Biliary stent placement is a well-established 
technique for palliation of patients with inoperable 
DMBO and both PSs and SEMSs are routinely used in 
current practice.
PSs diameters range from 7 Fr to 12 Fr. Any further 
increase in PS diameter larger than 10 Fr increases 
the technical difficulty of placement without improving 
stent patency. Therefore, a diameter of 10 Fr is 
thought to be the best combination of patency and 
technical ease of placement[62].
PSs of 10 Fr have patency rates of approximately 3 
mo, are very effective and are inexpensive, however, 
the short duration of stent patency remains a drawback.
Metal stents, in their fully expanded state, have a 
lumen diameter three to four times that of PSs. In a 
recent meta-analyses SEMSs were associated with a 
significantly longer stent patency (P < 0.001), lower 
reintervention rate (P = 0.001) and longer patient 
survival (P = 0.014) in palliation of patients with DMBO 
when compared to PSs[63].
Therefore, placement of SEMS for palliation of 
DMBO should be considered especially for patients 
with a predicted life expectancy of more than 3-4 mo. 
Uncovered, PC and FC-SEMS are used for palliation of 
patients with DMBO.
SEMS failure is usually related to tissue ingrowth 
using the uncovered type, while migration is usually 
the cause of stent failure using the covered type.
A meta-analysis including only randomized con-
trolled trials that compared stent patency duration and 
rates of covered vs USEMSs demonstrates that there 
are no differences in the patency rates at 6 or 12 mo 
between the two types of stents[64]. There were no 
differences in the rates of pancreatitis, cholecystitis, 
perforation, bleeding, cholangitis, or recurrent biliary 
obstruction, as well as no differences in durations of 
survival or hospital stay, but covered SEMS migrated 
significantly more frequently than USEMS[64]. There 
was a decrease in tissue ingrowth but an increased risk 
of tissue overgrowth in the covered SEMS group when 
compared with the USEMS group[64].
Two recently randomized trials showed that the 
stent patency rate was higher in covered SEMSs 
compared to USEMSs[65,66].
Hu et al[65], compared the use of a PC-SEMS with 
an antireflux valve with an USEMS for the palliation 
of DMBO and showed that the PC-SEMS has longer 
patency and reduces the risk of ascending cholangitis.
Kitano et al[66], in another randomized trial demon-
strated that for palliation of patients with DMBO, PC-
SEMSs with an antimigration system had a significantly 
longer duration of patency (P = 0.019) than USEMSs 
(median: 583 d vs 314 d, respectively) with absence 
of stent migration.
Stent migration mostly affects the patency of 
covered SEMSs and among the findings reported by 
Kitano et al[66], of particular interest is the absence of 
migration even with the use of PC-SEMSs.
The risk of migration is related to the conformability 
of the SEMS in the bile duct, which is influenced by the 
axial force exerted by the stent.
Stents with high axial force, such as the older 
stainless steel SEMS, do not conform to the curved 
bile duct, thus increasing the risk of adverse events 
especially migration.
Thus, the use of nitinol SEMSs could reduce migration 
rates, as demonstrated in a recent randomized trial by 
Soderlund et al[67], that compared the patency rate, 
patients survival, and adverse events in patients 
with DMBO and palliated with PC-SEMS made from 
stainless steel or nitinol and showed that stent failure 
occurred more often in the stainless steel PCSEMS 
group compared with the nitinol PC-SEMS group (P = 
0.02); stent migration occurred in 13 patients in the 
stainless steel group and in 3 patients in the nitinol 
group (P = 0.01).
An increased rate of late adverse events was also 
demonstrated in a previous retrospective study that 
compared the use of nitinol and stainless steel USEMS 
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in malignant biliary obstruction[68].
Biliary stenting is a proven technique for drainage 
of patients with unresectable DMBO, but its role for 
preoperative drainage in patients with resectable 
disease who are favorable surgical candidates remains 
a matter for debate.
A recent meta-analysis on the effect of preoperative 
biliary stenting on patients with obstructive jaundice 
suggest that the drainage should be applied selectively, 
the drainage time should be > 4 wk and that the 
SEMSs should be used for drainage[69].
Indeed Sun et al[69] compared patients who 
underwent preoperative drainage to those who did 
not have preoperative drainage and found overall 
mortality, overall morbidity, infectious morbidity, 
incidence of wound infection, intra-abdominal abscess, 
pancreatic fistulas, bile leak, and delayed gastric 
emptying were not significantly different. Compared 
with the non-drainage group, the drainage group had 
a drainage time of < 4 wk with an increased overall 
morbidity by 7% to 23%, while the overall morbidity 
of the drainage group with a drainage time > 4 wk was 
not significantly different[69]. Compared with the non-
drainage group, the overall mortality of the drainage 
group using SEMSs and PSs as drainage was reduced 
by 0.5% to 6%, whereas that of the drainage group 
using PSs was not significantly different[69].
The groups of patients who may benefit from 
preoperative biliary stenting are those with resectable 
disease in whom surgery is delayed (e.g., scheduling 
reasons, further preoperative staging, with underlying 
comorbidities that require optimization and even 
improvement in nutritional status) and those with 
locally advanced or borderline resectable disease 
requiring neoadjuvant chemotherapy[70].
Metal stents are preferred in these patients because 
their greater patency rates have shown a cost-benefit 
advantage in comparison to PSs[71].
Hilar malignant biliary obstruction (HMBO) can be 
caused by a group of heterogeneous tumors that in-
clude cholangiocarcinoma, cancer involving the hepatic 
confluence by direct extension from gallbladder, liver, 
and metastatic diseases and is classified according to 
Bismuth and Corlette into four types[72].
Type Ⅰ lesions is located below the confluence of 
hepatic ducts, type Ⅱ lesions includes the confluence 
but do not involve the left or right segmental hepatic 
ducts, type Ⅲ lesions occlude the common hepatic 
duct and either the right (Ⅲa) or left (Ⅲb) segmental 
hepatic ducts and type Ⅳ lesions are multicentric or 
involve the radicals on both sides.
This classification is helpful in determining and 
planning endoscopic stent placement.
Both PSs and USEMSs are used for drainage and 
palliation of HMBO as to not occlude drainage from the 
contralateral biliary system.
In patients with type Ⅰ lesions jaundice can be 
easily palliated using a single biliary stent, while 
palliation of the other types of lesions, especially type 
Ⅲ and Ⅳ, poses particular difficulties.
In these patients, the risk of incomplete drainage 
after contrast injection into the biliary system leads to 
a high incidence of post-procedure cholangitis and for 
this reason placement of 2 (or sometimes more) stents 
to drain each occluded segment has been proposed.
Pre-procedure imaging with computed tomography 
and MRCP is helpful to decide which obstructed 
segments should be drained and how many stents 
may be needed. It is important to realize that relief 
of jaundice generally requires drainage of about 50% 
of healthy liver or proportionally more in those with 
underlying dysfunction[73,74].
Therefore, the decision whether to place a single 
biliary stent or multiple stents depends on the location 
of strictures, the volume of liver that can be drained to 
relieve jaundice, and the introduction of contrast into 
more than 1 segment[75].
The success rate of PS insertion for HMBO is lower 
than that of DMBO, although relief of symptoms with 
improvement in quality of life can be achieved in nearly 
all patients successfully treated[76].
The use of SEMSs for palliation of HMBO is associated 
with a significantly longer stent patency (P = 0.009) and 
longer patient survival (P = 0.025) when compared to 
PSs[63].
In HMBO, SEMSs have been also demonstrated to 
be more cost-effective and require less subsequent 
interventions than PSs[77].
In systematic review (10 trials) by Hong et al[78], 
endoscopic placement of SEMSs was associated 
with a significantly higher successful drainage rate, 
lower early adverse event rate, longer stent patency 
and longer patient survival than PS placement. The 
unilateral biliary stenting group achieved a significantly 
higher successful stent insertion rate compared with 
the bilateral stenting group, whereas no difference was 
observed between groups with respect to successful 
drainage rate, early and late adverse events, stent 
patency and patient survival[78].
In another recent meta-analysis (36 studies: 
13 for bilateral SEMSs, 8 for unilateral SEMSs, 8 for 
bilateral PSs and 7 for unilateral PSs) that compared 
bilateral and unilateral stenting in HMBO, bilateral 
metal stenting had a lower odds of overall adverse 
events and an higher odds of lowering bilirubin levels 
than unilateral metal stenting, but the 30-d mortality 
was no different[79]. When analyzing the use of PSs 
separately, unilateral stenting was comparable to 
bilateral stenting in terms of success, overall adverse 
events, cholangitis, and 30-d mortality[79].
Various bilateral drainage techniques and newly 
developed SEMSs are now available.
Bilateral BD with SEMS can be performed by using 
one of two methods, the side-by-side (SBS) and stent-
in-stent (SIS) methods.
The technical success rate of both bilateral drainage 
techniques range from 73.3% to 100%, with a 
functional success rate between 75% and 100%[80].
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In a recent quantitative review and meta-analysis of 
the published data regarding the clinical efficacy of the 
SBS and SIS techniques for achieving bilateral drainage 
for HMBO, no significant differences with respect to 
the rates of successful placement, successful drainage, 
early and late adverse events, stent occlusion, stent 
patency and patient survival were seen between the 
two drainage techniques[81].
The need for preoperative BD of resectable HMBO 
is still controversial.
In a meta-analysis of 11 studies evaluating the 
benefit of preoperative BD in HMBO, routine per-
formance of preoperative drainage was not shown 
to be beneficial[82]. In this meta-analysis comparing 
preoperative BD to no preoperative BD, Liu et al[82], not 
demonstrate a decrease in mortality or postoperative 
hospital stay in patients undergoing preoperative 
drainage and in addition there was an increase in 
postoperative adverse event rates and infectious 
morbidity in the preoperative drainage group.
However preoperative BD is strongly recommended 
in selected patients such as those undergoing right 
lobectomy for lesions type ⅢA or Ⅳ, preoperative 
portal vein embolization with chemoradiation therapy, 
biliary infection due to undrained biliary segments and 
presence of severe pruritus[83].
Controversy remains regarding the use of ES 
before the placement of biliary stents.
A meta-analysis of randomized controlled trials 
that compared the clinical outcomes of patients who 
underwent ES with those that did not undergo ES 
before stent placement showed the incidence of post-
ERCP pancreatitis was significantly lower with ES, the 
incidence of bleeding was significantly higher in ES 
group, with no significant difference in stent migration 
and occlusion[84].
When transpapillary stent placement via ERCP 
fails, owing to anatomical or technical problems such 
as upper intestinal obstruction, surgically altered 
anatomy, periampullary diverticulum, or periampullary 
tumor infiltration, EUS-BD is a good option for biliary 
decompression in patients with both distal and HMBO[85].
The mean technical and clinical success rates of 
EUS-guided BD are 91% and 88% respectively, with a 
mean overall complication rate of 26% and a mortality 
of 0.4%[86]. Three different EUS-BD approaches have 
been described: transgastric [hepaticogastrostomy 
(HPG)], transduodenal (choledochoduodenostomy) 
stenting, and rendezvous technique[86]. The rendezvous 
approach is preferred by many endoscopists because it 
avoids a permanent transluminal fistula which may lead 
to adverse events[86].
Khashab et al[87], in a retrospective series, found no 
differences between rendezvous and direct transluminal 
approach in effectiveness and safety.
Artifon et al[88], in a recent randomized trial compared 
the outcomes of HPG and choledoco-duodenostomy 
(CLD) in patients with unresectable DMBO and suggested 
that the choice of approach should be left to the 
endoscopist. They reported a technical success rate of 
96% for HPG and 91% for CLD, a clinical success rate of 
91% for HPG and 77% for CLD, with a mean procedural 
time of 47.8 minutes for HPG and 48.8 min for CLD[88]. 
The adverse event rate was 20% for the HPG group and 
12.5% for the CLD group[88].
Various types of stents, including PSs, USEMS, and 
PC and FC-SEMS were used for the EUS-BD[89-92].
No comparative studies exist, but there appears to 
be a tendency to use covered SEMSs, instead of PSs.
Partially or FC-SEMSs appears to be a better option 
for three reasons: firstly, upon full expansion SEMS 
effectively seal the puncture/dilation tract, which 
theoretically prevents leakage; secondly, their larger 
diameter provides better long-term patency, which 
would decrease the need for SEMS revisions; finally, 
if dysfunction by tissue growth or clogging occurs, 
management is somewhat less challenging than with 
PSs, since a new stent can easily be inserted through 
the occluded SEMS[93-96].
However, migration can result in serious adverse 
events that can still occur even with the use of a PC or 
FCSEMS, especially early after the procedure. Proximal 
or distal SEMS migration caused by a shortening of 
the stent after deployment may lead to bile leakage 
into the peritoneal cavity and lead to fatal adverse 
events[97-99].
To prevent and reduce this complication two new 
types of hybrid (distal portion covered and proximal 
portion uncovered) SEMSs with antimigration systems 
were developed and preliminary outcomes showed no 
migration and bile leakage[100-102].
Recently, LAMSs were used for EUS-BD to prevent 
migration and bile leakage[103-106].
BENIGN PANCREATIC DISEASES
Benign pancreatic duct obstruction
Benign pancreatic duct obstruction (BPDO) may be the 
end-result of several different inflammatory processes 
with stricture formation, from severe acute pancreatitis 
and ductal disruption, relapsing acute pancreatitis or 
CP.
Endoscopic placement of PSs and covered SEMs 
have been used[107].
In the case of CP, BPDO may be caused by strictures, 
stones, or a combination of both.
Temporary placement of PS has become the 
standard of care for the endoscopic treatment of MPD 
strictures in CP. Different protocols have been used at 
different centers.
PS can remain in place for fixed intervals or ex-
changed only when symptoms recur[108].
The European Society of Gastrointestinal Endoscopy 
(ESGE) guidelines recommend treatment of the 
dominant MPD stricture in patients with CP by inserting 
a single 10 Fr PS, with stent exchange planned within 1 
year even in asymptomatic patients to prevent adverse 
events related to longstanding PS occlusion[109].
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The placement of PSs in the MPD is technically 
successful in greater than 90% of attempted cases 
and is followed by immediate and long-term pain 
relief in approximately 80% and 50% of patients, 
respectively[110].
When endoscopic treatment with a single PS fails, 
placement of multiple stents for 6-12 mo is another 
option.
Costamagna et al[111] described placement of multiple 
8.5-Fr to 11.5-Fr PSs in 19 patients previously treated 
with one PS, of whom 84% remained asymptomatic 
during a follow-up period of 3 years.
This multiple PSs approach is currently used in 
several centers and might decrease the need for 
repeated stent exchange. It is thought that pancreatic 
juice is able to flow between the stents into the 
duodenum even when occluded. This strategy might 
be particularly useful not only in patients with MPD 
strictures persisting after 12 mo of single PS but also 
in patients with a pancreas divisum because this 
anatomy is associated with more frequent stricture 
relapse and pain after PS removal compared with a 
fused pancreas[112].
When adequate stricture dilation with PSs is not 
achieved, placement of FC-SEMS into the MPD for 2 to 
3 mo is another potential option[113-117].
However, in a recent systematic review no significant 
difference between the two endoscopic treatment 
methods was seen[118]. Indeed, the technical success 
rate was 100% in both groups, the immediate clinical 
success rate was 100% in FCSEMS and 94.7% in 
multiple PSs, the migration rate was 8.2% for FCSEMS 
and 10.5% for multiple PSs, the re-intervention rate 
was 9.8% for FCSEMS and 15.8% for multiple PSs and 
pain improvement rate was 85.2% for FCSEMS and 
84.2% for multiple PSs[118].
Placement of one or more PS into the MPD is also 
performed for temporary decompression in patients 
with BPDO due to stones, before extracorporeal shock 
wave lithotripsy or at the time of ERCP to allow for 
passage of additional stone fragments and allow for 
ductal decompression and prevention of pancreatitis 
secondary to edema from the performance of pancreatic 
sphincterotomy[119].
Recently temporary placement of a FCSEMS in 
the MPD was also used for aiding extraction of large 
pancreatic duct stones[120].
When transpapillary pancreatic duct stenting fails 
or is not possible because of postsurgical anatomy, 
EUS pancreatic duct drainage (PDD) is a good option 
to treat the BPDO, due to stone or MPD stricture from 
CP, but also due to post-surgical pancreaticojejunal or 
pancreaticogastric anastomotic stenosis[121].
However EUS-PDD is a challenging procedure with 
a technical success rate ranging between 58% and 
100%, a clinical success rate ranging between 53% 
and 100% and a mean adverse event rate of 20%[86].
Technical failures are related to difficulty in orienting 
the echoendoscope along the axis of the MPD, inability 
to dilate the transmural tract because of dense fibrosis, 
and difficulty because of the acute angle at which the 
MPD is accessed at EUS[122].
Only PSs are used for this purpose, however a high 
rate of stent dysfunction, migration and duct leaks are 
reported and numerous endoscopic re-interventions 
are required[86].
Recently the use of a dedicated pancreatic duct 
stent designed for EUS-PDD was reported, but the 
single operator inclusion, small sample size (only 8 
patients) and lack of a control group limit generalization 
of results of this study[123]. However, the technical 
success of 100%, clinical success of 100%, and only 
one mild early adverse event (abdominal pain) and 
no late adverse events during a mean follow-up of 
7.4 mo suggest this new stent is effective and safe for 
EUS-PDD[123].
Pancreatic leaks/fistulae
Pancreatic fistula is defined as leakage of pancreatic 
fluid as a result of pancreatic duct disruption[124].
Ductal disruptions may be a result from acute and 
CP, abdominal trauma, following abdominal surgery 
and after pancreatic surgery[125].
Manifestations of pancreatic duct leakage include 
PFCs, pancreatic ascites, high amylase pleural 
effusions, and internal and external pancreatic fistulae.
Endoscopic treatment of pancreatic fistula is most 
commonly performed using PSs placed through the 
major or minor papilla. Stent placement promotes 
duct healing by diverting the flow across the leak site 
and traversing strictures and the pancreatic sphincter 
into the duodenum. Endoscopic transpapillary drainage 
is preferable for treatment of small communicating 
PFCs (< 6 cm) without solid debris and for treatment 
of pancreatic ascites, pleural effusion, and external 
fistula when there is a ductal disruption and no PFC. 
The success rate of endoscopic transpapillary drainage 
alone for PFCs ranges from 48% to 100%, 55% to 
100% for pancreatic ascites and pleural effusions and 
55% to 100% for external fistula[126].
Ductal disruptions refractory to PSs placement can 
be treated with placement of covered SEMS. Indeed 
there have been case reports describing successful 
healing of refractory pancreatic fistulas by placement 
of both PC and FC-SEMS[127-129].
When transpapillary stenting fails, especially in 
cases of disconnected duct syndrome (a duct leak 
with a complete transection of the MPD resulting in 
an isolated segment of the proximal portion of the 
pancreas) EUS-PDD is a good alternative endoscopic 
approach[130].
Pancreas divisum
For patients with symptomatic pancreas divisum (acute 
recurrent pancreatitis, CP, or chronic abdominal pain) 
endoscopic therapy is a safe and effective option, with 
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the best results seen in patients with acute recurrent 
pancreatitis[131].
Dorsal duct stenting in patients with pancreas divisum 
and CP decreased overall pain level, pain medication 
usage, and the number of hospital admissions per year 
with an improvement in nausea, vomiting and chronic 
pain[132].
For dorsal duct stenting a 5 Fr, 7 Fr or 10 Fr PSs is 
placed with or without minor papilla sphincterotomy 
or with minor papilla balloon dilation, with a clinical 
success rate of 54% and 90%[133-138].
Although PSs placement may decrease the number 
of episodes of pancreatitis, particularly for patients 
with recurrent pancreatitis, it may result in ductal 
damage that resembles CP and may be persistent in 
some cases[139].
In patients with pancreas divisum and CP the 
FCSEMS have been used for relief of abdominal pain 
that persisted despite pancreatic PSs implantation[140].
Prevention of post-ERCP pancreatitis
Pancreatic duct stenting has been increasingly used for 
prevention of PEP. Pancreatic duct stents are thought to 
reduce the incidence and severity of PEP by facilitating 
ductal drainage, relieving ductal hypertension from 
transient procedure-induced stenosis of the pancreatic 
orifice or over-injection of contrast[141].
There are now several robust studies that confirm 
the effectiveness of pancreatic duct stenting in 
preventing PEP, especially in patients at high-risk for 
PEP[142-144].
The most recent meta-analysis, which included 14 
randomized controlled trials involving 1541 patients 
demonstrated that PS placement prevented post-ERCP 
pancreatitis compared to no PS placement (7% vs 
19%; P < 0.001)[145]. Moreover this is the first meta-
analysis with sufficient power to demonstrate that 
pancreatic stenting is effective in preventing both mild 
to moderate and severe PEP[145].
A recent study show that urgent placement or 
replacement of pancreatic stents shortly after ERCP 
attenuates the course of evolving PEP with a statistically 
significant improvement in pain, amylase, lipase, 
and resolution of systemic inflammatory response 
syndrome[146].
Small caliber, short and softer 3 Fr or 5 Fr stents are 
most commonly used due to their ease of placement 
and higher rate of spontaneous migration compared to 
longer stents[147].
A systematic review and network meta-analysis 
suggest that stent diameter is more important for the 
prevention of PEP than stent design and presence of 
flanges[148].
In this study the use of 5 Fr stent was superior to 
the 3 Fr stent for the prevention of PEP in high-risk 
patients, and the 5 Fr single-pigtail, unflanged stent 
and 5 Fr straight, flanged stent performed similarly[148]. 
Both performed better than the 3 Fr stent in preventing 
post-ERCP pancreatitis[148].
Pancreatic stenting is recommended in patients 
with difficult cannulation, including double-wire 
cannulation, precut sphincterotomy, pancreatic (major 
or minor) sphincterotomy, pancreatic endotherapy, 
diagnostic or therapeutic ERCP for suspected or 
confirmed sphincter of Oddi dysfunction, history of 
PEP, balloon dilation of an intact biliary sphincter, and 
endoscopic ampullectomy[149].
PFCs
Indications for PFCs drainage include development 
of persistent symptoms thought to be related to 
the presence of the collection or development of 
a complications related to the collection such as 
infection, bleeding, biliary, or gastric outlet obstruction.
For drainage of PFCs the decision of which endoscopic 
approach to use is based on the anatomical relationship 
of the PFC to the alimentary canal, the presence of 
ductal system communication, and the size of the 
collection.
Transpapillary stenting can be considered in case 
of a PFC communication with the pancreatic ductal 
system, located in the pancreatic head and is the 
sole means of drainage if the PFC is smaller (< 6 
cm), or if transmural stenting is not feasible owing to 
distance (e.g., > 1 cm from the enteral lumen) or is 
contraindicated (e.g., severe coagulopathy)[150,151] with 
outcomes described above.
In cases of large PFCs with a visible bulge transmural 
drainage should be the first approach, and both EUS-
guided and non-EUS-guided techniques are used.
However EUS-guided drainage of PFCs showed 
superior technical and treatment success rates and 
more favorable safety profiles than traditional non-EUS 
approaches.
Varadarajulu et al[152] in 2008 published the first 
RCT; 30 patients were randomized to undergo PFC 
drainage by EUS (15) or non-EUS guided drainage (15) 
over a 6-mo period. Of the 15 patients randomized 
to EUS, drainage was not undertaken in one because 
an alternative diagnosis was made. All 14 patients 
randomized to EUS-guided technique underwent 
successful drainage (100%), while the procedure was 
technically successful in only 5 of 15 patients (33%) 
randomized to non-EUS guided drainage group. All 
10 patients who failed drainage by non-EUS guided 
technique underwent successful PFC drainage on 
crossover to EUS. Major procedure-related bleeding 
was encountered in 2 patients in whom non-EUS 
guided technique was performed.
Mangiavillano et al[153], in a series of 21 patients, 
showed as the technique of single-step EUS-guided 
drainage was superior to the two-step EUS-guided 
drainage for PFCs drainage.
Park et al[154] enrolled 60 consecutive patients with 
PFCs, which were randomly divided into two groups 
to undergo either EUS guided (31) or non-EUS guided 
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technique (29).
The rate of technically successful drainage was 
significantly higher for the EUS group (94%) than 
for the non-EUS guided technique group (72%) (P = 
0.039) in intention-to-treat analysis. In cases where 
non-EUS guided technique failed (8 cases) because the 
PFCs were non-bulging, a crossover was made to EUS 
guided technique, which was successfully performed 
in all these patients. Adverse events occurred in 7% of 
the EUS group and in 10% of the non-EUS group (P = 
0.67). During follow-up, PFC resolution was achieved 
in 97% in the EUS group and in 91% in the non-EUS 
group (P = 0.565).
A meta-analysis confirmed the superior technical 
and treatment success rates and more favorable 
safety profiles of the EUS guided drainage of PFCs than 
traditional non-EUS guided technique[155].
The mean technical and clinical success rates 
reported for EUS guided drainage of PFCs were 97% 
and 90% respectively, the mean overall adverse event 
rate was 17% and the mean overall recurrence rate 
was 8%[86]. The main potential adverse events are 
bleeding, superinfection, stent migration, perforation 
and pneumoperitoneum[86].
Many aspects of EUS guided drainage of PFCs have 
yet to be determined, such as optimal stent size and 
number, stent type (plastic or metal), as well as stent 
placement duration.
Evidence supports that keeping PSs in place 
after PFCs resolution maintains the cystenterostomy 
tract[156].
For PFCs which contain only fluid (e.g., pseudocysts) 
the treatment success rates are very high, while for 
PFCs in which at EUS the contents are not completely 
anechoic and contain solid material consistent with 
necrotic tissue, such as pancreatic abscesses or walled-
off pancreatic necrosis, clinical resolution is much less 
than with pseudocysts[157,158].
Traditionally, double pigtail PSs were used for PFC 
drainage. These stents provide highly secured drainage 
preventing dislocation and migration.
However, because of their limited size of up to 
only 10 Fr, these stents are prone to occlusion and 
endoscopic access to the PFC cavity via the fistula is 
limited.
Siddiqui et al[159], in a retrospective study, demon-
strated that patients with PFCs containing viscous 
solid debris-laden fluid, EUS guided drainage via a 
nasocystic irrigation tube alongside transmural stents 
resulted in a lower stent occlusion rate and better 
short-term clinical outcomes compared to transmural 
stents alone.
Therefore is has been suggested that placement 
of larger or multiple PSs and a nasocystic drainage 
catheter may facilitate resolution of PFCs, especially 
those containing significant debris.
Varadarajulu et al[160], showed that the necrotic 
collections drained with two to three transmural tracts, 
with multiple PSs in each track and a nasocystic 
irrigation tube, had a better outcomes compared with 
necrotic collections treated by conventional drainage 
techniques. Thus it appears that irrigation improves 
drainage of the necrotic contents.
Unfortunately, during placement of multiple PSs 
guidewire access may be lost, proximal migration 
of the first stent into the collection may occur, and 
additional procedural time is required.
Recently FCSEMSs, traditionally used for the 
treatment of a biliary diseases, have been used for 
drainage of PFCs[161-163].
A FCSEMS can be an alternative to conventional 
drainage with PSs because it offers the option of a 
larger-diameter access fistula for drainage and may 
increase the final success rate while it reduces the time 
to PFC resolution. In addition, only one passage of the 
guidewire is needed for placement.
In a systematic review of seventeen studies (881 
patients) there was no difference in overall treatment 
success between patients treated with PSs and 
FCSEMSs (81% vs 82%) for both pseudocysts (85% 
vs 83%) and walled-off necrosis (70% vs 78%), no 
difference in adverse event rates (16% vs 23%) and 
recurrence rates (10% vs 9%)[164].
Using biliary FCSEMs for PFCs drainage, partial 
or full migration remains a potentially significant 
problem. When these stents are used for PFCs, the 
longer protrusion on both the gastrointestinal tract 
and the cavity sides entails a risk of contact ulceration, 
bleeding, and migration.
Lee et al[165], in a recent prospective randomized 
study compared multiple PSs (25 cases) with a new 
designed FC-SEMSs (25 cases) for the drainage of 
PFCs, showed that the median procedure time with 
FC-SEMS was significantly shorter than with PSs (15 
min vs 29.5 min; P < 0.01), the technical success rate 
was 100% for both groups, the clinical success rate 
was 80% for both groups, no adverse events occurred 
in the FCSEMS group, while adverse events occurred in 
2 patients in the PSs group (P = 0.16), one recurrence 
was observed during follow-up in the FC-SEMS group 
and none in the PSs group (P = 0.15).
More recently, new dedicated LAMSs for drainage 
of PFCs, have been developed.
They have a large diameter, a saddle-shape design, 
with bilateral flanges, and a short length between 
flanges.
The flanges are designed to provide stent stability 
with a lumen-to-lumen anchoring effect (to distribute 
pressure evenly on the luminal wall and securely 
anchor the stent), thereby reducing the risk of 
migration and leakage alongside the stent and are fully 
covered to prevent tissue ingrowth and to enable easy 
removal[166].
Several studies have evaluated safety and efficacy 
of LAMSs for EUS-GD drainage of PFCs and reported 
technical success rates ranging between 89% and 
100%, clinical success rates ranging between 77% and 
100% and adverse event rates ranging between 9% 
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and 25%[167-171].
The large diameter of LAMSs enables direct 
insertion of an endoscope through the lumen of the 
stent for performing necrosectomy[172,173].
MALIGNANT PANCREATIC DISEASES
Malignant pancreatic duct obstruction (MPDO) is 
commonly seen in pancreatic cancer, particularly when 
the tumor is located in the pancreatic head, and may 
cause pancreatic duct dilation and “obstructive type” 
pain[174].
Both PSs (5 Fr to 11.5 Fr in size) and SEMSs have 
been used for decompression of the pancreatic duct in 
MPDO, with technical success rates ranging between 
81% and 100%, an improvement in pain in between 
61% and 100% and an improvement in quality of life 
in the majority of patients[175-177].
When failure to achieve access to MPD during 
ERCP occurs because of either failed cannulation or an 
inaccessible papilla from altered anatomy or proximal 
duodenal obstruction caused by tumour invasion, 
MPDO can be treated also with EUS-PDD[178].
CONCLUSION
Advances in stent design have led to a substantial 
increase in their use for a variety of benign and malignant 
pancreticobiliary diseases.
Endoscopic stenting has largely replaced surgery 
and interventional radiologic management of most 
pancreaticobiliary diseases both malignant (palliation of 
biliary strictures) and benign (treatment of strictures, 
leaks and collections).
The advent of metal stents has revolutionized the 
approach to these diseases, showing promising results 
even for the treatment of benign disorders.
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